KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Equity (2016 - 2025)

Historic Return on Equity for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to 0.02%.

  • Supernus Pharmaceuticals' Return on Equity fell 800.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 0.08% for FY2024, which is 700.0% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Return on Equity is 0.02%, which was down 800.0% from 0.06% recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Return on Equity registered a high of 0.15% during Q1 2021, and its lowest value of 0.02% during Q3 2025.
  • Its 5-year average for Return on Equity is 0.06%, with a median of 0.06% in 2024.
  • In the last 5 years, Supernus Pharmaceuticals' Return on Equity tumbled by -1100bps in 2021 and then soared by 800bps in 2025.
  • Supernus Pharmaceuticals' Return on Equity (Quarter) stood at 0.07% in 2021, then rose by 6bps to 0.07% in 2022, then crashed by -98bps to 0.0% in 2023, then skyrocketed by 5062bps to 0.07% in 2024, then plummeted by -125bps to 0.02% in 2025.
  • Its last three reported values are 0.02% in Q3 2025, 0.06% for Q2 2025, and 0.06% during Q1 2025.